Unregulated Stem Cell Clinics: Documented Cases of Serious Harm
The promise of regenerative medicine is real — but so are the risks when biologic material is sold and administered outside the bounds of regulation, characterization, and proper screening. There are documented, well-reported cases in which patients were seriously and permanently harmed at unapproved or poorly regulated stem cell clinics. This page summarizes several of them, because patient safety and rigorous standards are the foundation of responsible regenerative science. It is educational and provided for research and awareness purposes.
Important context: The cases below involve cell-based procedures marketed as treatments by clinics operating outside FDA approval. They are a cautionary illustration of what happens without proper standards — not a comparison to any specific product. BioRegenEx supplies MSC-derived exosomes strictly for research use only; our material is not a treatment and is not FDA-approved for any condition.
Documented cases of serious harm
1. Three patients permanently blinded after stem cell eye injections
In a case reported in the New England Journal of Medicine (2017), three women aged 72–88 with age-related macular degeneration received injections of their own fat- and blood-derived cells into both eyes at a Florida clinic (US Stem Cell, formerly Bioheart). Each paid about $5,000 and believed they were enrolling in a federally monitored trial. Within days they developed retinal detachment, hemorrhage, and rapidly worsening vision — all three were left with severe, permanent vision loss. The FDA later took successful legal action against the clinic.
2. Serious bacterial infections and sepsis from contaminated cord-blood products
In 2018–2019, the CDC and FDA documented at least 12 people across Arizona, Florida, and Texas who were hospitalized with bloodstream and other bacterial infections (including E. coli, Enterococcus faecalis, and Proteus mirabilis) after receiving umbilical cord-blood-derived products. One patient was hospitalized for nearly two months. FDA investigation found the processor had failed to properly screen donors for infectious diseases such as HIV and hepatitis. The products (the ReGen series, processed by Genetech and distributed by Liveyon) were recalled.
3. Embolism, stroke, organ failure, and death
FDA safety communications and published adverse-event reviews of unapproved stem cell interventions have described severe systemic complications — including pulmonary embolism, stroke, cardiac events, organ failure, paralysis, and, in some reports, death. These outcomes are most often associated with products and procedures that lack manufacturing controls, characterization, and regulatory oversight.
4. Tumor and abnormal tissue growth
Medical case reports have documented tumors, abnormal tissue growths, and lesions developing after certain stem cell interventions — including a widely cited report of a spinal-cord growth following stem cell “tourism” abroad. Such outcomes are a particular concern when living cells are extensively manipulated or administered outside established protocols.
5. A patient death after a spinal stem cell injection
In 2019, a 62-year-old Colorado man died after receiving a spinal injection of stem cells at a Seattle clinic. Evidence later presented at trial showed the procedure was performed without imaging guidance while the patient was taking blood-thinning medication, causing catastrophic bleeding and fatal brain herniation. In 2026 his family was awarded $24 million, and state regulators separately took action against the clinic for deceptively marketing unproven treatments. (News coverage)
6. Spinal-cord growth after “stem cell tourism”
A case reported in the New England Journal of Medicine (2016) described a man who developed a glioproliferative lesion — an abnormal proliferating growth — of the spinal cord after receiving intrathecal infusions of mesenchymal, embryonic, and fetal stem cells at commercial clinics in China, Argentina, and Mexico. He developed progressive back pain, paralysis, and incontinence; molecular analysis indicated the growth originated from the introduced cells. (NEJM, 2016)
7. An intramedullary spinal-cord mass years later
A separate published case described an 18-year-old woman who, eight years after an experimental olfactory-cell implantation at the site of a spinal cord injury, developed an intramedullary spinal-cord mass at the implantation site that required surgical resection — an illustration that complications can emerge years after a procedure.
A documented pattern, not isolated incidents. These are not one-off anecdotes. A Pew Charitable Trusts analysis catalogued hundreds of reported adverse events tied to unapproved stem cell interventions, and the FDA has issued dozens of warning letters to clinics and manufacturers marketing unapproved stem cell products for serious conditions.
Regulators are taking action — often over the claims
The response from federal and state regulators has been escalating. Notably, much of the legal jeopardy targets the marketing claims, not only the procedures themselves:
FTC v. Regenerative Medical Group (2019)
The FTC charged a physician and his companies for deceptively advertising “amniotic stem cell therapy” as a treatment for Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, and heart disease — without the scientific evidence to support those claims. The order imposed a $3.31 million judgment, with funds directed to consumer refunds. (FTC)
FTC & Georgia AG v. Stem Cell Institute of America (2021–2025)
Co-founders who trained practitioners to market unproven stem cell therapy — largely to older and disabled adults — were banned from marketing stem cell treatments and ordered to pay more than $5.1 million in civil penalties and refunds to hundreds of consumers. (FTC)
The throughline across FDA, FTC, and state attorneys general is consistent: the exposure frequently comes from unsupported claims. This is precisely why responsible suppliers keep material research-use-only, document everything, and avoid treatment claims — and why every marketing claim in this space deserves scrutiny before it ships.
The common thread
Across these cases, the same risk factors appear again and again: material sold without FDA approval, marketed as a treatment, administered with inadequate donor screening, no manufacturing controls, and no meaningful characterization or release testing. The danger was not “regenerative medicine” as a field — it was the absence of the standards that responsible science depends on.
Why standards exist — and why they matter
This is the entire reason characterization, sterility and endotoxin testing, donor traceability, regulatory clarity, and honest research-use-only labeling exist. They are not bureaucratic boxes; they are what separates legitimate biologic research material from the products at the center of the cases above. When evaluating any supplier or provider, the right questions are concrete: Is the material characterized and documented? Is it sterility- and endotoxin-tested per lot? Is the donor screened and traceable? Is it honestly represented — or marketed with treatment claims it cannot support?
BioRegenEx supplies MSC-derived exosomes as research-use-only material, with per-lot documentation, precisely because the credibility and safety of this field depend on those standards. We do not market our material as a treatment, and we encourage patients and physicians alike to be rigorous.
Authoritative resources
- FDA — Consumer information on regenerative medicine and unapproved stem cell products
- FDA — FDA warns about unproven stem cell therapies
- NPR coverage of the NEJM blindness report — “3 Women Blinded By Unproven Stem Cell Treatments”
- CDC — reports on infections linked to stem cell and exosome products
Frequently Asked Questions
Are these cases about exosomes?
No. These documented cases involve cell-based stem cell procedures marketed as treatments by unapproved clinics. They are presented here to illustrate why regulation, characterization, and screening matter. BioRegenEx supplies MSC-derived exosomes for research use only; our material is not a treatment.
Does this mean regenerative medicine is dangerous?
The danger in these cases came from the absence of standards — no FDA approval, no donor screening, no manufacturing controls, no characterization — not from regenerative science itself. Standards are what make the difference.
How can I avoid these risks?
Be rigorous. Ask whether material is characterized and documented, sterility- and endotoxin-tested, donor-screened and traceable, and honestly labeled. Be wary of anyone marketing unapproved biologics as a cure, and consult a qualified, licensed physician.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical or legal advice. If you are considering any regenerative procedure, consult a qualified, licensed physician.